Karim Fizazi, MD, PhD, on HRR-Deficient mCRPC: Final Overall Survival in TALAPRO-2

February 21, 2025 By The ASCO Post Staff

Karim Fizazi, MD, PhD, of Institut Gustave Roussy, University of Paris-Saclay, reviews final overall survival results from cohort 2 of the phase III TALAPRO-2 trial, which investigated the combination of talazoparib and enzalutamide in patients with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) (Abstract LBA141).

Related Content